Pipeline

Legal Disclaimer | Site Map | Contact
© 2007 CuraGen Corporation

June 11, 2008
CuraGen Presentation at the Needham 7th Annual Biotechnology & Medical Conference

CuraGen Corporation (NASDAQ: CRGN) is a clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. Strategic alliances forged by CuraGen have resulted in a pipeline of potential therapeutics that is being advanced by the Company's experienced team. CuraGen is currently conducting clinical trials with CR011-vcMMAE, an antibody-drug conjugate being developed for the treatment of melanoma, breast cancer and brain tumors. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its therapeutics toward the market and addressing the unmet medical needs of cancer patients.

Recent News

June 25, 2008
CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer

June 11, 2008
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma

June 6, 2008
CuraGen to Present at The Seventh Annual Needham & Company Biotechnology and Medical Technology Conference

Events

June 11, 2008
CuraGen Presentation at the Needham 7th Annual Biotechnology & Medical Conference

June 4, 2008
2008 ASCO Annual Meeting

Quotes delayed at least 20 minutes.
Information provided by TurboFeed.